Table of Contents
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of September, 2003
Commission File Number 000-31062
Oncolytics Biotech Inc.
(Translation of registrant’s name into English)
Suite 210, 1167 Kensington Crescent NW
Calgary, Alberta, Canada T2N 1X7
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
| Form 20-F þ | Form 40-F o |
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
| Yes o | No þ |
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82 -
| Signatures | ||||||||
| Media Release | ||||||||
Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Oncolytics
Biotech Inc. (Registrant) |
||||
| Date September 22, 2003 | By: | /s/ Douglas A. Ball
Douglas A. Ball Chief Financial Officer |
||
Table of Contents
 |
210, 1167 Kensington Crescent NW Calgary, Alberta Canada T2N 1X7 |
MEDIA ADVISORY
Oncolytics Biotech to Present at the
UBS Warburg Global Life Sciences Conference
CALGARY, Alberta, September 22, 2003 – Dr. Brad Thompson, Chairman, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate overview to analysts, portfolio managers, investment bankers and other financial professionals at the 5th Annual UBS Warburg Global Life Sciences Conference. The conference will be held at The Plaza Hotel in New York City on September 22-25, 2003. Dr. Thompson will make his presentation on Thursday, Sept. 25, 2003 at 2:30 p.m. ET.
A live audio webcast of the presentation will be available on the UBS website http://www.ibb.ubs.com/ or on the company’s website at www.oncolyticsbiotech.com. It is recommended that listeners log on 15 minutes in advance of the presentation to register and download any necessary software.
An audio replay of the presentation will begin three hours after the presentation time and will be available until October 25, 2003 on the UBS website.
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the development of REOLYSIN®, its proprietary formulation of the human reovirus, as a potential cancer therapeutic. Oncolytics’ researchers have demonstrated that the reovirus is able to selectively kill human cancer cells in vitro that are derived from many types of cancer, including breast, prostate, pancreatic and brain tumours, and have also demonstrated successful cancer treatment results in a number of animal models. Phase I clinical trial results have indicated that there were no toxicology-related issues with the administration of the reovirus, and that the reovirus demonstrated activity in tumours injected with REOLYSIN®.
The webcast time is subject to change. This release and the presentation related thereto contain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company’s control and which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or expectations implied by these forward-looking statements.
FOR FURTHER INFORMATION PLEASE CONTACT:
| For Canada: | For Canada: | For United States: | ||
| Oncolytics Biotech Inc. | The Equicom Group Inc. | The Investor Relations Group | ||
| Cathy Ward | Joanna Longo | Gino De Jesus or Dian Griesel, Ph.D. | ||
| 210, 1167 Kensington Cr NW | 20 Toronto Street | 11 Stone Street, 3rd Floor | ||
| Calgary, Alberta T2N 1X7 | Toronto, Ontario M5C 2B8 | New York, NY 10004 | ||
| Tel: 403.670.7377 | Tel: 416.815.0700 ext. 233 | Tel: 212.825.3210 | ||
| Fax: 403.283.0858 | Fax: 416.815.0080 | Fax: 212.825.3229 | ||
| info@oncolyticsbiotech.com | jlongo@equicomgroup.com | theproteam@aol.com |